Herz. 2026 Feb 27. doi: 10.1007/s00059-026-05373-x. Online ahead of print.
ABSTRACT
Severe tricuspid regurgitation (TR) is a common right-sided valvular disease associated with a substantially increased risk of morbidity, hospitalization, and mortality. Transcatheter tricuspid edge-to-edge repair (T-TEER) is a minimally invasive therapy for patients with severe, symptomatic TR at high surgical risk. By approximating the valve leaflets, T‑TEER reduces regurgitant volume, improves right heart hemodynamics, and interrupts the progressive cycle of right ventricular dilation and worsening TR. Studies and registry data show that approximately 81-88% of patients treated with T‑TEER achieve a reduction of TR to moderate or less, accompanied by sustained improvements in functional status, quality of life, right heart remodeling, and reductions in heart failure-related hospitalizations. Early analyses also suggest beneficial effects on renal and hepatic function. Therefore, T‑TEER represents a safe and effective treatment option for patients with severe TR who previously had limited therapeutic options.
PMID:41758333 | DOI:10.1007/s00059-026-05373-x